Parsons G, Ragbir C, D’Agnone O, et al. - Some limitations of oral therapy for opioid dependence (OD) treatment including stigma, difficulty in achieving consistent appropriate dosing, risk of diversion of medications, risk of overdose, and continuing use of other drugs can be addressed with administering prolonged-release buprenorphine (PRB), by weekly or monthly injection. Via this study, researchers sought to describe patient-reported outcomes (PRO) during PRB therapy that may aid in guiding future treatment decision-making. They conducted qualitative interviews among 15 individuals on PRB OD treatment who agreed to participate. Among 14 participants who completed interviews (average age: 42 (range 33– 54) years, 13 males and 1 woman), the history of problematic opioid use was 14 years (3– 25 years), time in treatment was 7 years (1– 20 years), and duration on treatment with PRB was 4 months (range 1– 8 months). Generally a positive level of treatment satisfaction was reported with PRB in this small, focused population. These experiences yield insights to explain potential treatment advantage to others and are valuable in guiding therapy choices for others in the future.